Cordis said that the Innovation trial (multicenter, open-label, prospective, non-randomized study of the Cordis AAA stent graft system in subjects with abdominal aortic aneurysm) is expected to enroll
Benitec said that the Phase I study utilises a triple vector which includes one component utilising Benitec’s DNA-directed RNA interference technology, along with two other proprietary RNA technologies
Bassam Damaj, president and chief executive officer of NexMed, said: “Our Bio-Quant business has experienced continuous growth during the past five years, including an increase of over 20%
Bassam Damaj, president and chief executive officer of NexMed, said: “Our Bio-Quant business has experienced continuous growth during the past five years, including an increase of over 20%
As per the terms of the agreement, Upsher-Smith is expected to undertake the clinical development, regulatory filing and commercialisation of Tonabersat for epilepsy in the USA, Canada and
As per the results, EG01257, a low nanomolar potent molecule, reduced the rate of tumour growth and showed no evidence of toxicity. NRP-1 is a therapeutic target of
HemCon’s product offerings include a full line of hemostatic dressings with antibacterial properties. The technology, originally developed for use on the battlefield to control severe hemorrhaging, is used
Suven Life Sciences said that the granted claims of the patent include the class of selective serotonin receptor affinity compounds discovered by Suven and are being developed as
Bausch + Lomb said that PreserVision Eye Vitamin and Mineral Supplement AREDS 2 formula will be on retail shelves in early May, 2010. Reportedly, scientific studies showed that
Al Dar Al Arabia was established in 2005 as a joint venture between APM, a wholly-owned subsidiary of Hikma and Dar Al Dawa. Al Dar Al Arabia owns
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.